Mississauga, Ontario

GenomeArc Inc., a leading biotech organization, is proud to announce the release of its cutting-edge genome interpretation software - Horizon, revolutionizing the field of genetic analysis. This breakthrough technology leverages advanced artificial intelligence and multivariate regression algorithms to provide highly accurate and insightful interpretations of clinical genomic data, while introducing a novel feature of embedded natural language processing to understand phenotypic correlation with numerous rare disorders and pan cancer.

Interpreting variants has long been a cornerstone in the quest for understanding human health, hereditary diseases, drug design and personalized medicine. However, the complex nature of genomic data often presents challenges in extracting biologically meaningful insights. Horizon platform addresses this by combining geneticist curated clinical genomic datasets from rare disorders, cancer and control cohorts, offering unparalleled accuracy and speed in deciphering the genetic code.

High variant classification accuracy leveraging advanced algorithms, and massive training clinical genomic datasets, Horizon achieves over 90% variant pathogenicity prediction accuracy comparing with clinical geneticists from multiple contents across the globe. Horizon integrates genome with phenotype for interpreting genomic data, enabling researchers and healthcare professionals to make more informed decisions based on comprehensive and reliable insights. Natural lagrange processing significantly enhances variant interpretation by seamlessly integrating disease symptom textual description with genetic variants.

Horizon is extremely fast and can classify an exome within few minutes using regular compute servers. This ultra-fast variant interpretation is exclusively important for neonatal and prenatal critical care unit (NICU and PICU) patients. Tumor profiling can be done in few minutes with great accuracy that will enable fast decision time for therapeutic intervention. Horizon allows to integrate custom population specific databases, and provides proprietary disease variant, multi-OMICs and pharmacogenomics databases to aid variant interpretations and disease management. Horizon prioritizes user experience, offering an intuitive and user-friendly interface that allows clinicians, geneticists, and researchers to easily navigate genomic variant databases. The interface is designed to streamline workflows, optimize data visualization, and facilitate collaboration among researchers in the field of genomics.

"Horizon platform provides a significant leap forward in analyzing genome for diagnosis and genomic medicine,” said Dr. Mohammed Dafil, founder of GenomeArc and a leading geneticist. "Fast, and accurate platform embedded with AI to interpret genomic variants will revolutionize NICU/PICU and cancer patients’ healthcare outcome".

Horizon platform is now available for commercial use, empowering researchers, clinicians, and biotechnology professionals to unlock the full potential of genomic data for improving human health.